Primary Progressive Multiple Sclerosis
Multiple sclerosis (MS) is an inflammatory and demyelinating disorder of the central nervous system. The majority of newly-diagnosed MS patients develop the relapsing remitting form of MS (RRMS), which is characterized by periods of neurological worsening followed by periods of spontaneous remission.
About 10-15% of all MS patients suffer from primary progressive multiple sclerosis (PPMS). This sub-type is characterized by a gradual progression of the neurological impairment from its onset with no superimposed relapses or remissions. While the cause of MS remains unclear, accumulating data indicate that, especially in progressive stages, mitochondrial dysfunction and oxidative stress may play a major role, particularly in the pathogenesis of PPMS.
There is currently no treatment available with proven therapeutic efficacy in PPMS, indicating a high unmet medical need for this devastating disease.
RaxoneŽ (idebenone) for the treatment of primary progressive Multiple Sclerosis
The IPPOMS (Idebenone in Patients with Primary Progressive Multiple Sclerosis) trial is a Phase II study with a 12-month pre-treatment baseline period followed by a double-blind, randomized, placebo-controlled treatment of 24 months duration investigating the safety and efficacy of high dose RaxoneŽ versus placebo.
This study is sponsored and conducted by the National Institute of Neurological Disorders and Stroke (NINDS). For more information about the IPPOMS study, please visit www.clinicaltrials.gov (Identifier NCT00950248).
United States of America
US National Institutes of Health
Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, 20892
Patient Recruitment and Public Liaison Office
Phone: +1 800 411-1222